Preview

Онкологическая колопроктология

Расширенный поиск

Локализация первичной опухоли толстой кишки: есть ли принципиальные отличия?

https://doi.org/10.17650/2220-3478-2017-7-3-35-48

Полный текст:

Аннотация

Рак толстой кишки представляет собой гетерогенное заболевание, каждый подтип которого имеет особенности клинической картины, чувствительности к той или иной терапии и, соответственно, различный прогноз. Таким образом, можно разделить опухоли в зависимости от локализации – исходящие из левых или правых отделов толстой кишки. Проксимальные и дистальные отделы толстой кишки имеют различный эмбриогенез, что определяет границу между правым и левым отделами на уровне дистальной и средней трети поперечной ободочной кишки. В литературе достаточно данных для того, чтобы говорить не только о наличии различий в эмбриогенезе. Опухоли толстой кишки, развивающиеся в правых и левых отделах, различаются эпидемиологически, клинико-патоморфологически, молекулярно-генетически. Это, возможно, определяет и различия подходов в скрининге, профилактике и лечении опухолей. Целью данного обзора явился анализ различий между опухолями толстой кишки с различной локализацией и определение, оказывает ли влияние на лечебные и профилактические подходы такое разделение рака толстой кишки в клинической практике.

Об авторах

М. Ю. Федянин
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России;
Россия
Россия, 115478 Москва, Каширское шоссе, 23


А. А. Трякин
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России;
Россия
Россия, 115478 Москва, Каширское шоссе, 23


С. А. Тюляндин
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России;
Россия
Россия, 115478 Москва, Каширское шоссе, 23


Список литературы

1. Benedix F., Schmidt U., Mroczkowski P. et al. Colon carcinoma – classification into right and left sided cancer or according to colonic subside? Analysis of 29,568 patients. Eur J Surg Oncol 2011;37(2):134–9. DOI: 10.1016/j.ejso.2010.12.004.

2. Bufill J.A. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113(10):779–88. PMID: 2240880.

3. Benedix F., Kube R., Meyer F. et al. Comparison of 17,641 patients with rightand left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010;53(1):57–64. DOI: 10.1007/DCR.0b013e3181c703a4.

4. Konopke R., Distler M., Ludwig S., Kersting S. Location of liver metastases reflects the side of the primary colorectal carcinoma. Scand J Gastroenterol 2008;43(2):192–5. DOI: 10.1080/00365520701677755. PMID: 17918001.

5. Teixeira Y., Lima J.M., Souza M.L. et al. Human DNA quantification in the stools of patients with colorectal cancer. Arq Gastroenterol 2015;52(4):293–8. DOI: 10.1590/S0004-28032015000400008. PMID: 26840470.

6. Graziano F., Ruzzo A., Giacomini E. et al. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Pharmacogenomics J 2017;17(3):258–64. DOI: 10.1038/tpj.2016.13.

7. Xu S.Z., Ding Z.J., Zhang S.F. et al. Propensity score matching-based analysis of short-term outcomes of Laparoscopicassisted Natural Orifice Specimen Extraction for left colorectal cancer radical resection. Zhonghua Yi Xue Za Zhi 2016;96(20):1578–81. DOI: 10.3760/cma.j.issn.0376-2491. 2016.20.007.

8. Tie J., Gibbs P., Lipton L. et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF (V600E) mutation. Int J Cancer 2011;128(9):2075–84. DOI: 10.1002/ijc.25555.

9. Guinney J., Dienstmann R., Wang X. et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21(11):1350–6. DOI: 10.1038/nm.3967.

10. Maus M.K., Hanna D.L., Stephens C.L. et al. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 2015;15(4):354–62. DOI: 10.1038/tpj.2014.73.

11. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101(5):403–8. DOI: 10.1002/ijc.10635. PMID: 12216066.

12. Glebov O.K., Rodriguez L.M., Nakahara K. et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 2003;12(8):755–62. PMID: 12917207.

13. Birkenkamp-Demtroder K., Olesen S.H., Sorensen F.B. et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005;54(3):374–84. DOI: 10.1136/gut.2003.036848. PMID: 15710986.

14. Yamauchi M., Morikawa T., Kuchiba A. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61(6):847–54. DOI: 10.1136/gutjnl-2011-300865.

15. Missiaglia E., Jacobs B., D’Ario G. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25(10):1995–2001. DOI: 10.1093/annonc/mdu275.

16. Lee M., Advani S., Morris J. et al. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. J Clin Oncol 2016;34(Suppl):3506–3506.

17. Cheng L., Eng C., Nieman L.Z. et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34(6):573–80. DOI: 10.1097/COC.0b013e3181fe41ed.

18. Baxter N.N., Goldwasser M.A., Paszat L.F. et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150(1):1–8. PMID: 19075198.

19. Brenner H., Hoffmeister M., Arndt V. et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010;102(2):89–95. DOI: 10.1093/jnci/djp436.

20. Yang J., Du X.L., Li S.T. et al. Characteristics of Differently Located Colorectal Cancers Support Proximal and Distal Classification: A Population-Based Study of 57,847 Patients. PLoS One 2016;11(12):e0167540. DOI: 10.1371/journal.pone.0167540.

21. Meguid R.A., Slidell M.B., Wolfgang C.L. et al. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 2008;15(9):2388–94. DOI: 10.1245/s10434-008-0015-y.

22. Weiss J.M., Pfau P.R., O’Connor E.S. et al. Mortality by stage for right- versus leftsided colon cancer: analysis of surveillance, epidemiology, and end results. Medicare data. J Clin Oncol 2011;29(33):4401–9. DOI: 10.1200/JCO.2011.36.4414.

23. Taieb J., Kourie H.R., Emile J.-F. et al. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. J Clin Oncol 2017;35(15 suppl):3515– 3515. PMID: 26705231.

24. Wang M.J., Ping J., Li Y. et al. Prognostic significance and molecular features of colorectal mucinous adenocarcinomas: a strobe-compliant study. Medicine 2015; 94(51):e2350. DOI: 10.1097/MD.0000000000002350.

25. Tarantino I., Huttner F.J., Warschkow R. et al. Prognostic Relevance of Mucinous Subtype in a Population-based Propensity Score Analysis of 40,083 Rectal Cancer Patients. Ann Surg Oncol 2016;23(5):1576–86. DOI: 10.1245/s10434-015-5029-7.

26. Huh J.W., Kim H.C., Kim S.H. et al. Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: predictive role of lymph node metastasis and survival. J Surg Oncol 2014;109(8):848–52.

27. Saltzstein S.L., Behling C.A. Age and time as factors in the left-to-right shift of the subside of colorectal adenocarcinoma: a study of 213,383 cases from the California Cancer Registry. J Clin Gastroenterol 2007;41(2):173–7. DOI: 10.1097/01.mcg.0000225550.26751.6a. PMID: 17245216.

28. Benedix F., Meyer F., Kube R. et al. Rightand left-sided colonic cancer – different tumour entities. Zentralbl Chir 2010;135(4):312–7. DOI: 10.1055/s-0030-1247471.

29. Jess P., Hansen I.O., Gamborg M. et al. A nationwide Danish cohort study challenging the categorization into right-sided and left-sided colon cancer. BMJ Open 2013;3. pii: e002608.. DOI: 10.1136/bmjopen-2013-002608.

30. Christodoulidis G., Spyridakis M., Symeonidis D. et al. Clinicopathological differences between right- and left-sided colonic tumors and impact upon survival. Tech Coloproctol 2010;14:S45–7. DOI: 10.1007/s10151-010-0622-z.

31. Mik M., Berut M., Dziki L. et al. Rightand left-sided colon cancer – clinical and pathological differences of the disease entity in one organ. Arch Med Sci 2017;13(1):157–62. DOI: 10.5114/aoms.2016.58596.

32. Brenner H., Altenhofen L., Katalinic A. et al. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. Am J Epidemiol 2011;174(10):1140–6. DOI: 10.1093/aje/kwr188.

33. Singh H., Nugent Z., Demers A.A., Bernstein C.N. Rate and predictors of early/ missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol 2010;105(12):2588–96. DOI: 10.1038/ajg.2010.390.

34. Tarraga Lopez P.J., Albero J.S., Rodriguez-Montes J.A. Primary and secondary prevention of colorectal cancer. Clin Med Ins Gastroenterol 2014;7:33–46. DOI: 10.4137/CGast.S14039.

35. Steffen A., Weber M.F., Roder D.M., Banks E. Colorectal cancer screening and subsequent incidence of colorectal cancer: results from the 45 and Up Study. Med J Aust 2014;201(9):523–7. PMID: 25358576.

36. Agesen T.H., Sveen A., Merok M.A. et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012;1(11):1560–7. DOI: 10.1136/gutjnl-2011-301179. PMID: 22213796.

37. De Kort S., Simons C.C., van den Brandt P.A. et al. Diabetes mellitus type 2 and subsitespecific colorectal cancer risk in men and women: results from the Netherlands Cohort Study on diet and cancer. Eur J Gastroenterol Hepatol 2016;28(8):896–903. DOI: 10.1097/MEG.0000000000000626.

38. Nayani R., Ashktorab H., Brim H., Laiyemo A.O. Genetic Basis for Colorectal Cancer Disparities. Curr Colorectal Cancer Rep 2015;11(6):408–13. DOI: 10.1007/s11888-015-0302-5. PMID: 26997937.

39. Gao Z., Guo B., Gao R. et al. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol 2015;6:20. DOI: 10.3389/fmicb.2015.00020.

40. Sears C.L., Geis A.L., Housseau F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest 2014;124(10):4166–72. DOI: 10.1172/JCI72334.

41. Hwang S., Gwon S.Y., Kim M.S. et al. Bacteroides fragilis Toxin Induces IL-8 Secretion in HT29/C1 Cells through Disruption of E-cadherin Junctions. Immune Netw 2013;13(5):213–7. DOI: 10.4110/in.2013.13.5.213.

42. Wu S., Powell J., Mathioudakis N. et al. Bacteroides fragilis enterotoxin induces intestinal epithelial cell secretion of interleukin-8 through mitogen-activated protein kinases and a tyrosine kinase-regulated nuclear factor-kappa B pathway. Infect Immun 2004;72(10):5832–9. DOI: 10.1128/IAI.72.10.5832-5839.2004. PMID: 15385484.

43. Sanfilippo L., Li C.K., Seth R. et al. Bacteroides fragilis enterotoxin induces the expression of IL-8 and transforming growth factor-beta (TGF-beta) by human colonic epithelial cells. Clin Exp Immunol 2000;119(3):456–63. PMID: 10691917.

44. Purcell R.V., Pearson J., Aitchison A. et al. Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. PloS One 2017;12(2):e0171602. DOI: 10.1371/journal.pone.0171602.

45. Boleij A., Hechenbleikner E.M., Goodwin A.C. et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 2015;60(2):208–15. DOI: 10.1093/cid/ciu787.

46. Viljoen K.S., Dakshinamurthy A., Goldberg P., Blackburn J.M. Quantitative profiling of colorectal cancerassociated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PloS One 2015;10(3):e0119462. DOI: 10.1371/journal.pone.0119462.

47. Dejea C.M., Wick E.C., Hechenbleikner E.M. et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA 2014;111(51):18321–6. DOI: 10.1073/pnas.1406199111.

48. LaPointe L.C., Dunne R., Brown G.S. et al. Map of differential transcript expression in the normal human large intestine. Physiol Genomics 2008;33(1):50–64. DOI: 10.1152/physiolgenomics.00185.2006. PMID: 18056783.

49. Mao Q., Unadkat J.D. Role of the breast cancer resistance protein (BCRP/ ABCG2) in drug transport-an update. AAPS J 2015;17(1):65–82. DOI: 10.1208/s12248-014-9668-6.

50. Kosaka T., Mikami S., Yoshimine S. et al. The prognostic significance of OCT4 expression in patients with prostate cancer. Hum Pathol 2016;51:1–8. DOI: 10.1016/j.humpath.2015.12.008.

51. Hu J., Li J., Yue X. et al. Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes. Oncotarget 2017;8(17):28463–70.

52. Yang J.F., Noffsinger A.E., Agrawal D., Yang Q.-H. Colorectal cancer anatomic distribution patterns remain the same after sessile serrated adenoma/polyp considered cancer precursor: a 9-year comparison study from community-based endoscopy centers. J Gastrointest Oncol 2016;7(6):917–23. DOI: 10.21037/jgo.2016.07.02.

53. Kim S.E., Paik H.Y., Yoon H. et al. Sexand gender-specific disparities in colorectal cancer risk. World J Gastroenterol 2015;21(17):5167–75. DOI: 10.3748/wjg.v21.i17.5167.

54. Samowitz W.S., Curtin K., Schaffer D. et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:1193–7. PMID: 11097226.

55. Hutchins G., Southward K., Handley K. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29(10):1261–70. DOI: 10.1200/JCO.2010.30.1366.

56. Peng J., Huang D., Poston G. et al. The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients. Oncotarget 2017;8(30):49076–83. DOI: 10.18632/oncotarget.16176.

57. Sinicrope F.A., Shi Q., Allegra C.J. et al. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 2017;3(4):472–80. DOI: 10.1001/jamaoncol.2016.5469.

58. Tran B., Kopetz S., Tie J. et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117(20):4623–32. DOI: 10.1002/cncr.26086.

59. Atreya C.E., Greene C., McWhirter R.M. et al. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. J Natl Compr Canc Netw 2016;14(12):1536–43. PMID: 27956538.

60. Wang L., Cunningham J.M., Winters J.L. et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209–5212. PMID: 28748988.

61. Roth A., Tejpar S., Delorenzi M. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2009;28(3):466–74. DOI: 10.1200/JCO.2009.23.3452.

62. Roth A., Klingbiel D., Yan P. et al. Molecular and clinical determinants of survival following relapse after curative treatment of stage II–III colon cancer (CC): results of the translational study of PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2010;28(Suppl):5248–57.

63. Tejpar S. The multidisciplinary management of gastrointestinal cancer. The use of molecular markers in the diagnosis and treatment of colorectal cancer. Best Pract Res Clin Gastroenterol 2007;21(6):1071–87. DOI: 10.1016/j.bpg.2007.10.002. PMID: 18070704.

64. Popovici V., Budinska E., Tejpar S. et al. Identification of a poor-prognosis BRAFmutant-like population of patients with colon cancer. J Clin Oncol 2012;30:1288–95. DOI: 10.1200/JCO.2011.39.5814.

65. Paski S.C., Wightman R., Robert M.E. et al. The importance of recognizing increased cecal inflammation in health and avoiding the misdiagnosis of nonspecific colitis. Am J Gastroenterol 2007;102(10):2294–9. DOI: 10.1111/j.1572-0241.2007.01389.x. PMID: 17608777.

66. Kirby J.A., Bone M., Robertson H. et al. The number of intraepithelial T cells decreases from ascending colon to rectum. J Clin Pathol 2003;56(2):158. PMID: 12560402.

67. Mancini S., Mariani F., Sena P. et al. Myeloperoxidase expression in human colonic mucosa is related to systemic oxidative balance in healthy subjects. Redox Rep 2017:1–9. DOI: 10.1080/13510002.2016.1277049.

68. Vather R., Sammour T., Kahokehr A. et al. Lymph node evaluation and long-term survival in stage II and stage III colon cancer: a national study. Ann Surg Oncol 2008;16(3):585–93. DOI: 10.1245/s10434-008-0265-8.

69. Moro-Valdezate D., Pla-Martí V., MartínArévalo J. et al. Factors related to lymph node harvest: does a recovery of more than 12 improve the outcome of colorectal cancer? Colorectal Dis 2013;15(10):1257–66. DOI: 10.1111/codi.12424.

70. Fan L., Levy M., Aguilar C.E. et al. Lymph node retrieval from colorectal resection specimens for adenocarcinoma: is it worth the extra effort to find at least 12 nodes? Colorectal Dis 2011;13(12):1377–83. DOI: 10.1111/j.1463-1318.2010.02472.x.

71. Gonsalves W.I., Kanuri S., Tashi T. et al. Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: a veterans’ affairs central cancer registry (VACCR) database analysis. J Surg Oncol 2011;104(6):667–71. DOI: 10.1002/jso.21886.

72. Kuo Y.-H., Lee K.-F., Chin C.-C. et al. Does body mass index impact the number of LNs harvested and influence long-term survival rate in patients with stage III colon cancer? Int J Colorectal Dis 2012;27(12):1625–35. DOI: 10.1007/s00384-012-1496-5.

73. Chou J.F., Row D., Gonen M. et al. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer 2010;116(11):2560–70. DOI: 10.1002/cncr.25032.

74. Kim Y.W., Jan K.M., Jung D.H. et al. Histological inflammatory cell infiltration is associated with the number of lymph nodes retrieved in colorectal cancer. Anticancer Res 2013;33(11):5143–50. PMID: 24222162.

75. Sarli L., Bader G., Iusco D. et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005;41(2):272–9. DOI: 10.1016/j.ejca.2004.10.010. PMID: 15661553.

76. Bilimoria K.Y., Palis B., Stewart A.K. et al. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum 2008;51(2):154–61. DOI: 10.1007/s10350-007-9114-2.

77. Destri G.L., Di Carlo I., Scilletta R. et al Colorectal cancer and lymph nodes: the obsession with the number 12. World J Gastroenterol 2014;20(8):1951–60. DOI: 10.3748/wjg.v20.i8.1951.

78. Nawa T., Kato J., Kawamoto H. et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol 2008;23(3):418–23. DOI: 10.1111/j.1440-1746.2007.04923.x. PMID: 17532785.

79. Hansen I.O., Jess P. Possible better longterm survival in left versus right-sided colon cancer – a systematic review. Dan Med J 2012;59:A4444. PMID: 22677242.

80. Wong H.L., Lee B., Field K. et al. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clin Colorectal Cancer 2016;15(2):e9–e15. DOI: 10.1016/j.clcc.2016.02.007.

81. Boisen M.K., Johansen J.S., Dehlendorff C. et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013;24(10):2554–9. DOI: 10.1093/annonc/mdt253.

82. Loupakis F., Yang D., Yau L. et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015;107(3):dju427. DOI: 10.1093/jnci/dju427.

83. Lenz H.J., Lee F.C., Yau L. et al. MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2016;34(suppl 4S): abstr 493.

84. Goey K.K.H., Elias S.G., van Tinteren H. et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol 2017;mdx322.

85. Wirapati P., Pomella V., Vandenbosch B. et al. Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol 2017;35(15 suppl):3538–3538.

86. Portnoy D.C., Obermannova R., Bodoky G. et al. Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI. J Clin Oncol 2017;35(4_suppl):668–668.

87. Grothey A., Van Cutsem E., Sobrero A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (correct): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303–12. DOI: 10.1016/S0140-6736(12)61900-X.

88. Chen K.H., Shao Y.Y., Chen H.M. et al. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC cancer 2016;16:327. DOI: 10.1186/s12885-016-2358-2.

89. Moretto R., Cremolini C., Rossini D. et al. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF WildType Metastatic Colorectal Cancer. Oncologist 2016;21(8):988–94. DOI: 10.1634/theoncologist.2016-0084.

90. Wang F., Bai L., Liu T.S. et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer 2015;34(9):384–93. DOI: 10.1186/s40880-015-0022-x.

91. Brule S.Y., Jonker D.J., Karapetis C.S. et al. Location of colon cancer (right sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015;51(11):1405–14. DOI: 10.1016/j.ejca.2015.03.015.

92. Seligmann J.F. Primary Tumour Location (PTL) as a prognostic and predictive factor in advanced colorectal cancer: data from 2075 patients in randomised trials. Ann Oncol 2014;25(suppl 4):iv172.

93. Arnold D., Lueza B., Douillard J.Y. et al. Prognostic and predictive value of primary tumour side in patients with RAS wildtype metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Ann Oncol 2017. [Epub ahead of print].

94. Boeckx N., Koukakis R., Op de Beeck K. et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol 2017. [Epub ahead of print].

95. Boeckx N., Toler A., Op de Beeck K. et al. Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC. Ann Oncol 2016;27(6):15–42.

96. Tejpar S., Stintzing S., Ciardiello F. et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2016. DOI: 10.1001/jamaoncol.2016.3797.

97. Holch J.W., Ricard I., Stintzing S. et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 2017;70:87–98. DOI: 10.1016/j.ejca.2016.10.007.

98. Venook A.P., Niedzwiecki D., Innocenti F. et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016;34(suppl):abstr 3504.

99. Schwartzberg L.S., Rivera F., Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wildtype KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32(21):2240–7. DOI: 10.1200/JCO.2013.53.2473.

100. Adam R., De Gramont A., Figueras J. et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17(10):1225–39. DOI: 10.1634/theoncologist.2012-0121.

101. Heinemann V., Stintzing S., Modest D.P. et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 2015;51(14):1927–36. DOI: 10.1016/j.ejca.2015.06.116.

102. Cremolini C., Loupakis F., Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as firstline treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16(13):1306–15. DOI: 10.1016/S1470-2045(15)00122-9.

103. Van Cutsem E., Cervantes A., Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27(8): 1386–422. DOI: 10.1093/annonc/mdw235.

104. Khattak M.A., Martin H., Davidson A., Phillips M. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer 2015;14(2):81–90. DOI: 10.1016/j.clcc.2014.12.011.

105. Rivera F., Karthaus M., Hecht J.R. et al. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wildtype (WT) RAS metastatic colorectal carcinoma (mCRC): tumor response outcomes beyond RECIST. J Clin Oncol 2015;33(suppl 3): abstr 660.


Для цитирования:


Федянин М.Ю., Трякин А.А., Тюляндин С.А. Локализация первичной опухоли толстой кишки: есть ли принципиальные отличия? Онкологическая колопроктология. 2017;7(3):35-48. https://doi.org/10.17650/2220-3478-2017-7-3-35-48

For citation:


Fedyanin M.Y., Tryakin A.A., Tjulandin S.A. Localization of the primary tumor of the colon: аre there essential differences? Colorectal Oncology. 2017;7(3):35-48. (In Russ.) https://doi.org/10.17650/2220-3478-2017-7-3-35-48

Просмотров: 151


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2413-0583 (Online)